vs
渤健（BIIB）与TRINITY BIOTECH PLC（TRIB）财务数据对比。点击上方公司名可切换其他公司
渤健的季度营收约是TRINITY BIOTECH PLC的74.6倍（$2.3B vs $30.5M）。渤健净利率更高（-2.1% vs -33.0%，领先30.8%）。渤健自由现金流更多（$468.0M vs $-4.1M）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
Trinity Biotech PLC是一家全球体外诊断企业，研发、生产和销售适用于临床实验室与床旁检测场景的诊断试剂盒及配套系统，产品线覆盖糖尿病管理、传染病、心脏健康、自身免疫疾病等领域，主要市场包括北美、欧洲及全球新兴经济体。
BIIB vs TRIB — 直观对比
营收规模更大
BIIB
是对方的74.6倍
$30.5M
净利率更高
BIIB
高出30.8%
-33.0%
自由现金流更多
BIIB
多$472.1M
$-4.1M
损益表 — Q4 2025 vs Q2 2024
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $30.5M |
| 净利润 | $-48.9M | $-10.1M |
| 毛利率 | 78.3% | 36.8% |
| 营业利润率 | -2.5% | -23.2% |
| 净利率 | -2.1% | -33.0% |
| 营收同比 | -7.1% | — |
| 净利润同比 | -118.3% | — |
| 每股收益（稀释后） | $-0.35 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBTRIB
| Q4 25 | $2.3B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.6B | — | ||
| Q1 25 | $2.4B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | $30.5M | ||
| Q1 24 | $2.3B | — |
净利润BIIBTRIB
| Q4 25 | $-48.9M | — | ||
| Q3 25 | $466.5M | — | ||
| Q2 25 | $634.8M | — | ||
| Q1 25 | $240.5M | — | ||
| Q4 24 | $266.7M | — | ||
| Q3 24 | $388.5M | — | ||
| Q2 24 | $583.6M | $-10.1M | ||
| Q1 24 | $393.4M | — |
毛利率BIIBTRIB
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | 36.8% | ||
| Q1 24 | 76.3% | — |
营业利润率BIIBTRIB
| Q4 25 | -2.5% | — | ||
| Q3 25 | 22.0% | — | ||
| Q2 25 | 28.1% | — | ||
| Q1 25 | 12.8% | — | ||
| Q4 24 | 11.9% | — | ||
| Q3 24 | 18.3% | — | ||
| Q2 24 | 28.3% | -23.2% | ||
| Q1 24 | 20.3% | — |
净利率BIIBTRIB
| Q4 25 | -2.1% | — | ||
| Q3 25 | 18.4% | — | ||
| Q2 25 | 24.0% | — | ||
| Q1 25 | 9.9% | — | ||
| Q4 24 | 10.9% | — | ||
| Q3 24 | 15.8% | — | ||
| Q2 24 | 23.7% | -33.0% | ||
| Q1 24 | 17.2% | — |
每股收益（稀释后）BIIBTRIB
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $3.17 | — | ||
| Q2 25 | $4.33 | — | ||
| Q1 25 | $1.64 | — | ||
| Q4 24 | $1.82 | — | ||
| Q3 24 | $2.66 | — | ||
| Q2 24 | $4.00 | — | ||
| Q1 24 | $2.70 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $5.3M |
| 总债务越低越好 | $6.3B | — |
| 股东权益账面价值 | $18.3B | $-29.4M |
| 总资产 | $29.4B | $94.4M |
| 负债/权益比越低杠杆越低 | 0.34× | — |
8季度趋势，按日历期对齐
现金及短期投资BIIBTRIB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $5.3M | ||
| Q1 24 | — | — |
总债务BIIBTRIB
| Q4 25 | $6.3B | — | ||
| Q3 25 | $6.3B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $6.3B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $6.3B | — | ||
| Q1 24 | $6.3B | — |
股东权益BIIBTRIB
| Q4 25 | $18.3B | — | ||
| Q3 25 | $18.2B | — | ||
| Q2 25 | $17.6B | — | ||
| Q1 25 | $17.0B | — | ||
| Q4 24 | $16.7B | — | ||
| Q3 24 | $16.4B | — | ||
| Q2 24 | $15.9B | $-29.4M | ||
| Q1 24 | $15.2B | — |
总资产BIIBTRIB
| Q4 25 | $29.4B | — | ||
| Q3 25 | $29.2B | — | ||
| Q2 25 | $28.3B | — | ||
| Q1 25 | $28.0B | — | ||
| Q4 24 | $28.0B | — | ||
| Q3 24 | $28.3B | — | ||
| Q2 24 | $26.8B | $94.4M | ||
| Q1 24 | $26.6B | — |
负债/权益比BIIBTRIB
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.40× | — | ||
| Q1 24 | 0.41× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | $-3.9M |
| 自由现金流经营现金流 - 资本支出 | $468.0M | $-4.1M |
| 自由现金流率自由现金流/营收 | 20.5% | -13.3% |
| 资本支出强度资本支出/营收 | 1.9% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $2.1B | $-4.1M |
8季度趋势，按日历期对齐
经营现金流BIIBTRIB
| Q4 25 | $511.9M | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $160.9M | — | ||
| Q1 25 | $259.3M | — | ||
| Q4 24 | $760.9M | — | ||
| Q3 24 | $935.6M | — | ||
| Q2 24 | $625.8M | $-3.9M | ||
| Q1 24 | $553.2M | — |
自由现金流BIIBTRIB
| Q4 25 | $468.0M | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $134.3M | — | ||
| Q1 25 | $222.2M | — | ||
| Q4 24 | $721.6M | — | ||
| Q3 24 | $900.6M | — | ||
| Q2 24 | $592.3M | $-4.1M | ||
| Q1 24 | $507.3M | — |
自由现金流率BIIBTRIB
| Q4 25 | 20.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 9.1% | — | ||
| Q4 24 | 29.4% | — | ||
| Q3 24 | 36.5% | — | ||
| Q2 24 | 24.0% | -13.3% | ||
| Q1 24 | 22.1% | — |
资本支出强度BIIBTRIB
| Q4 25 | 1.9% | — | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | 1.4% | 0.5% | ||
| Q1 24 | 2.0% | — |
现金转化率BIIBTRIB
| Q4 25 | — | — | ||
| Q3 25 | 2.73× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 2.85× | — | ||
| Q3 24 | 2.41× | — | ||
| Q2 24 | 1.07× | — | ||
| Q1 24 | 1.41× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
TRIB
暂无分部数据
